Cargando…

Intrahepatic fatty acids composition as a biomarker of NAFLD progression from steatosis to NASH by using (1)H-MRS

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world and it is becoming one of the most frequent cause of liver transplantation. Unfortunately, the only available method that can reliably determine the stage of this disease is liver biopsy, however, it is invasive...

Descripción completa

Detalles Bibliográficos
Autores principales: Xavier, Aline, Zacconi, Flavia, Gainza, Constanza, Cabrera, Daniel, Arrese, Marco, Uribe, Sergio, Sing-Long, Carlos, Andia, Marcelo E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076551/
https://www.ncbi.nlm.nih.gov/pubmed/35542850
http://dx.doi.org/10.1039/c9ra08914d
_version_ 1784701949791174656
author Xavier, Aline
Zacconi, Flavia
Gainza, Constanza
Cabrera, Daniel
Arrese, Marco
Uribe, Sergio
Sing-Long, Carlos
Andia, Marcelo E.
author_facet Xavier, Aline
Zacconi, Flavia
Gainza, Constanza
Cabrera, Daniel
Arrese, Marco
Uribe, Sergio
Sing-Long, Carlos
Andia, Marcelo E.
author_sort Xavier, Aline
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world and it is becoming one of the most frequent cause of liver transplantation. Unfortunately, the only available method that can reliably determine the stage of this disease is liver biopsy, however, it is invasive and risky for patients. The purpose of this study is to investigate changes in the intracellular composition of the liver fatty acids during the progression of the NAFLD in a mouse model fed with Western diet, with the aim of identify non-invasive biomarkers of NAFLD progression based in (1)H-MRS. Our results showed that the intracellular liver fatty acid composition changes as NAFLD progresses from simple steatosis to steatohepatitis (NASH). Using principal component analysis with a clustering method, it was possible to identify the three most relevant clinical groups: normal, steatosis and NASH by using (1)H-MRS. These results showed a good agreement with the results obtained by GC-MS and histology. Our results suggest that it would be possible to detect the progression of simple steatosis to NASH using (1)H-MRS, that has the potential to be used routinely in clinical application for screening high-risk patients.
format Online
Article
Text
id pubmed-9076551
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90765512022-05-09 Intrahepatic fatty acids composition as a biomarker of NAFLD progression from steatosis to NASH by using (1)H-MRS Xavier, Aline Zacconi, Flavia Gainza, Constanza Cabrera, Daniel Arrese, Marco Uribe, Sergio Sing-Long, Carlos Andia, Marcelo E. RSC Adv Chemistry Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world and it is becoming one of the most frequent cause of liver transplantation. Unfortunately, the only available method that can reliably determine the stage of this disease is liver biopsy, however, it is invasive and risky for patients. The purpose of this study is to investigate changes in the intracellular composition of the liver fatty acids during the progression of the NAFLD in a mouse model fed with Western diet, with the aim of identify non-invasive biomarkers of NAFLD progression based in (1)H-MRS. Our results showed that the intracellular liver fatty acid composition changes as NAFLD progresses from simple steatosis to steatohepatitis (NASH). Using principal component analysis with a clustering method, it was possible to identify the three most relevant clinical groups: normal, steatosis and NASH by using (1)H-MRS. These results showed a good agreement with the results obtained by GC-MS and histology. Our results suggest that it would be possible to detect the progression of simple steatosis to NASH using (1)H-MRS, that has the potential to be used routinely in clinical application for screening high-risk patients. The Royal Society of Chemistry 2019-12-19 /pmc/articles/PMC9076551/ /pubmed/35542850 http://dx.doi.org/10.1039/c9ra08914d Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Xavier, Aline
Zacconi, Flavia
Gainza, Constanza
Cabrera, Daniel
Arrese, Marco
Uribe, Sergio
Sing-Long, Carlos
Andia, Marcelo E.
Intrahepatic fatty acids composition as a biomarker of NAFLD progression from steatosis to NASH by using (1)H-MRS
title Intrahepatic fatty acids composition as a biomarker of NAFLD progression from steatosis to NASH by using (1)H-MRS
title_full Intrahepatic fatty acids composition as a biomarker of NAFLD progression from steatosis to NASH by using (1)H-MRS
title_fullStr Intrahepatic fatty acids composition as a biomarker of NAFLD progression from steatosis to NASH by using (1)H-MRS
title_full_unstemmed Intrahepatic fatty acids composition as a biomarker of NAFLD progression from steatosis to NASH by using (1)H-MRS
title_short Intrahepatic fatty acids composition as a biomarker of NAFLD progression from steatosis to NASH by using (1)H-MRS
title_sort intrahepatic fatty acids composition as a biomarker of nafld progression from steatosis to nash by using (1)h-mrs
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076551/
https://www.ncbi.nlm.nih.gov/pubmed/35542850
http://dx.doi.org/10.1039/c9ra08914d
work_keys_str_mv AT xavieraline intrahepaticfattyacidscompositionasabiomarkerofnafldprogressionfromsteatosistonashbyusing1hmrs
AT zacconiflavia intrahepaticfattyacidscompositionasabiomarkerofnafldprogressionfromsteatosistonashbyusing1hmrs
AT gainzaconstanza intrahepaticfattyacidscompositionasabiomarkerofnafldprogressionfromsteatosistonashbyusing1hmrs
AT cabreradaniel intrahepaticfattyacidscompositionasabiomarkerofnafldprogressionfromsteatosistonashbyusing1hmrs
AT arresemarco intrahepaticfattyacidscompositionasabiomarkerofnafldprogressionfromsteatosistonashbyusing1hmrs
AT uribesergio intrahepaticfattyacidscompositionasabiomarkerofnafldprogressionfromsteatosistonashbyusing1hmrs
AT singlongcarlos intrahepaticfattyacidscompositionasabiomarkerofnafldprogressionfromsteatosistonashbyusing1hmrs
AT andiamarceloe intrahepaticfattyacidscompositionasabiomarkerofnafldprogressionfromsteatosistonashbyusing1hmrs